EQUIPE de rattachement :  Equipe 1 (A. Gaillard)

NOM Prénom :    PAIN Stéphanie

 Statut (date de début-fin prévue si CDD):   MCU en pharmacie spécialité toxicologie

Adresses : UFR Médecine-Pharmacie, Bâtiment D1 ; 6, rue de la milétrie, TSA 51115 86073 POITIERS Cedex 9

Laboratoire de Neurosciences Expérimentales et Cliniques INSERM U-1084, Bâtiment B36, 1 rue Georges Bonnet, BP 633

TSA 51106, 86073 POITIERS cedex9 – FRANCE

Tél :    05 49 44 38 36

05 49 36 62 13

e-mail : stephanie.pain@univ-poitiers.fr

Publications (toutes les marquantes, y compris avant 2012):

• Page G., Barc-Pain S., Pontcharraud R., Cante A., Piriou A., Barrier L. The up-regulation of the striatal dopamine transporter’s activity by cAMP is PKA-, CaMK II- and phosphatase-dependent. Neurochem. Int. (2004) 45: 627-632.
• Lafay-Chebassier C., Paccalin M., Page G., Barc-Pain S., Perault-Pochat MC., Gil R., Pradier L. Hugon J. Alteration of the mTOR/p70S6K signaling induced  exposure, in APP-PS1 transgenic models and in patients withbby A Alzheimer’s disease. J. Neurochem. (2005) 94: 215-225.
• Paccalin M., Pain-Barc S., Pluchon C., Paul C., Bazin H., Gil R., Hugon J. The relation between p70S6K expression in lymphocytes and the decline of cognitive tests in patients with Alzheimer disease. Arch. Int. Med. (2005) 165: 2428-2429.
• Paccalin M., Pain-Barc S., Pluchon C., Paul C., Besson M.N., Carret-Rebillat A.S., Rioux-Bilan A., Gil R., Hugon J. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord (2006). 22: 320-326.
• Deguil J., Jailloux D., Page G., Houeto J.L., Fauconneau B., Philippe M., Muller J-M., Pain S. Neuroprotective effects of PACAP in the MPP+-induced alteration of translational control in neuroblastoma cells. J. Neurosci. Res. (2007) 85: 2017-2025.
• Pain S., Barrier L., Deguil J., Milin S., Piriou A., Fauconneau B., Page G. A cell-permeable peptide inhibitor TAT-JBD reduces the MPP+-induced caspase 9 activation but does not prevent the dopaminergic degeneration in substantia nigra of rats. Toxicology, (2007) 243: 124-137.
• Deguil J., Chavant F., Lafay-Chebassier C., Pérault-Pochat MC., Fauconneau B., Pain S. Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox. Res. (2010) 17: 142-155.
• Deguil, F. Chavant, C. Lafay-Chebassier, MC. Pérault-Pochat, B. Fauconneau, S. Pain. Time course of MPTP toxicity on translational control protein expression in mice brain. Toxicol. Lett. (2010) 196: 51-55.
• Decressac M., Pain S., Chabeauti PY., Frangeul L., Thiriet N., Herzog H., Vergote J., Chalon S., Jaber M, Gaillard A. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson’s disease. Neurobiol. Aging (2012) 33: 2125-2137.
• Pain S., Gochard A., Bodard S., Gulhan Z., Prunier-Aesch C., Chalon S.. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson’s disease. Exp. Toxicol. Pathol. (2013) 65: 689-694.